Details for New Drug Application (NDA): 213714
✉ Email this page to a colleague
NDA 213714 describes ENALAPRIL MALEATE, which is a drug marketed by Alkem Labs Ltd, Amneal, Annora Pharma, Aurobindo Pharma, Bionpharma, Aiping Pharm Inc, Apothecon, Aurobindo Pharma Usa, Chartwell Rx, Heritage Pharma, Ivax Sub Teva Pharms, Krka Dd Novo Mesto, Mylan, Prinston Inc, Regcon Holdings, Sandoz Inc, Senores Pharms, Sun Pharm Inds Ltd, Taro, Unique Pharm, Watson Labs, Anda Repository, Cosette, Mpp Pharma, Rising, and Taro Pharm Inds, and is included in thirty NDAs. It is available from thirty-one suppliers. Additional details are available on the ENALAPRIL MALEATE profile page.
The generic ingredient in ENALAPRIL MALEATE is enalapril maleate; hydrochlorothiazide. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the enalapril maleate; hydrochlorothiazide profile page.
The generic ingredient in ENALAPRIL MALEATE is enalapril maleate; hydrochlorothiazide. There are twenty-seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the enalapril maleate; hydrochlorothiazide profile page.
Summary for 213714
| Tradename: | ENALAPRIL MALEATE |
| Applicant: | Alkem Labs Ltd |
| Ingredient: | enalapril maleate |
| Patents: | 0 |
Pharmacology for NDA: 213714
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
| Physiological Effect | Decreased Blood Pressure |
Medical Subject Heading (MeSH) Categories for 213714
Suppliers and Packaging for NDA: 213714
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ENALAPRIL MALEATE | enalapril maleate | SOLUTION;ORAL | 213714 | ANDA | Ascend Laboratories, LLC | 67877-712 | 67877-712-81 | 150 mL in 1 BOTTLE (67877-712-81) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 1MG/ML | ||||
| Approval Date: | Mar 30, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
